Contact US

Patient-derived cell model screening service
Progress your lead agent to clinical candidate with confidence

Access hundreds of PDC models

Ready to use at every stage of the drug discovery and development pipeline

Obtain pharmacology data that translate to clinical response with the only in vitro drug screening services using patient-derived cell (PDC) models.

predictTx Screen leverages the power of high-content imaging to provide key information on the cytotoxicity and chemotherapeutic potential of your agent early in the drug development process.

Enroll now

Benefit from:

  • Cost efficient screening service compared to stand-alone studies

  • Simple model selection from a panel of 50 well-characterised PDCs across 18 different solid tumour types

  • Model characterisation data including NGS, patient treatment history, in vitro drug response to standard of care

  • Proven predictive power over patient response in the clinic

  • 89% positive predictive value

  • 99% negative predictive value

  • Fast data turnaround

  • Scalable patient-derived models for dose escalation and repeat studies

  • Amenable to small molecule and biotherapeutics screening

Why use predictTx Screen

Our growing biobank of models is more than 90% accurate in predicting clinical response.

predictTx Screen key features

PDC development cycle


Find relevant therapies

1. Collect & Develop

Fresh tumour sample collected from patient, brought to our lab and developed into a PDC.

2. Analyse & Report

Around 60 drugs dosed on sample. Effects analysed using high-content screening. Results highlight suitable treatments and reported to oncologist.

3. Expand & Bank

PDC expanded and cryogenically preserved in Imagen biobank.


Rapid discovery and development of new therapies

1. Design Experiment

Agree objectives and select from 100’s of PDC models in our database (fully characterised, including WES/RNAseq).

2. Run Experiment

Re-derive and grow PDC models, dose according to protocol.

3. Analyse & Generate

Analyse data and generate endpoints (IC50’s, amongst others).

  • 2D assay format

  • Cell death and cell count read-out

  • Standard 3 days treatment, extendable to 7 days

  • 8-point dose response curve/drug

  • 10 models minimum from a 50 model panel

Enroll now
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound
Contact Us

© Copyright 2022 Imagen Therapeutics Ltd